• 1
    Walker MD, Alexander E Jr., Hung WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49: 333343.
  • 2
    Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 71: 25852597.
  • 3
    Buckner JC, Schomberg PJ, McCinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer. 2001; 92: 420433.
  • 4
    Galanis E, Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer. 2000; 82: 13711380.
  • 5
    Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572.
  • 6
    Buckner JC, O'Fallon JR, Novotny P, Schaefer PL, Scheithauer BW. Determinants of time to progression and overall survival of patients in clinical trials for recurrent glioma. Neurooncol. 2000; 2: 276 (A30).
  • 7
    Galanis E, Buckner J. Chemotherapy of brain tumors. Curr Opin Neurol. 2000; 13: 619625.
  • 8
    Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999; 17: 27622771.
  • 9
    Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol. 1998; 9: 845847.
  • 10
    Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999; 65: 576582.
  • 11
    Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997; 62: 287292.
  • 12
    Nagatsu S, Kondo S, Kondo Y, et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol. 1997; 39: 417423.
  • 13
    Houghton PJ, Cheshire PJ, Hallman JD 2nd, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995; 36: 393403.
  • 14
    Hare CB, Elion GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-peperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997; 39: 187191.
  • 15
    Castellino RC, Elion GB, Keir ST, et al. Schedule-dependent activity of irinotecan plus BCNU against human malignant glioma xenografts. Cancer Chemother Pharmacol. 2000; 45: 345349.
  • 16
    Coggins CA, Elion GB, Houghton PJ, et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998; 41: 485490.
  • 17
    Buckner J, Reid J, Schaaf L, et al. A phase II trial of irinotecan (CPT-11) in recurrent glioma [abstract 679A]. Proc Am Soc Clin Oncol. 2000; 19: 175a.
  • 18
    Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17: 15161525.
  • 19
    Reid J, Buckner J, Schaaf L, et al. Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: results of an NCCTG Phase II trial. Proc Am Soc Clin Oncol. 1999; 18: 141a.
  • 20
    Reid JM, Buckner JC, Schaaf LF, et al. Anticonvulsants alter the pharmacokinetics of irinotecan (CPT-11) in patients with recurrent glioma [abstract 620]. Proc Am Soc Clin Oncol. 2000; 19: 160a.
  • 21
    Bagniewski PG, Reid JM, Ames MM, Bonner JA, Buckner JC, Sloan JA. Increased etoposide clearance in patients with glioma may be associated with concurrent glucocorticoid or anticonvulsant treatment (poster presentation) [abstract 1224]. Proc Am Assoc Cancer Res. 1996; 37: 179.
  • 22
    Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium. J Clin Oncol. 1997; 15: 13211328.
  • 23
    Grossman SA, Hochberg F, Fisher J, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. Cancer Chemother Pharmacol. 1998; 42: 118126.
  • 24
    Kim JH, Kim SH, Kolozsvary BS, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys. 1992; 22: 515518.
  • 25
    Boothman DA, Wang M, Schea RA, Burrows HL, Strickfaden S, Owens JK. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys. 1992: 24: 939948.
  • 26
    Ng CE, Bussey AM, Raaphorst GP. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma and cell lines. Int J Radiat Biol Oncol Phys. 1994; 66: 4957.
  • 27
    Eder JP, Wong JS, Chan V, Teicher BA. Irinotecan and radiation in vitro and in vivo. Int J Oncol. 1997; 11: 12351240.
  • 28
    Lamond JP, Wang M, Kinsella TJ, Boothman DA. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys. 1996; 36: 369376.
  • 29
    Tamura K, Takada M, Kawase I, et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res. 1997; 88: 218223.
  • 30
    Sasai K, Guo GZ, Shibuya K, et al. Effects on SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation. Int J Radiat Oncol Biol Phys. 1998; 42: 785788.
  • 31
    Omura M, Torigoe S, Kubota N. SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates of cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother Oncol. 1997; 43: 197201.
  • 32
    Friedman HS, Quinn JA, Tourt-Uhlog S, et al. Phase I trial of CPT-11 plus BCNU in malignant glioma [abstract 253]. Proc Am Soc Clin Oncol. 2001; 20: 64a.
  • 33
    Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999; 91: 429433.
  • 34
    Yang C-HJ, Horton JK, Cowan KH, Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 1995; 55: 40044009.
  • 35
    Kellner U, Hutchinson L, Seidel A, et al. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of p-glycoprotein. Int J Cancer. 1997; 71: 817824.
  • 36
    Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone or doxorubicin. Cancer Res. 1999; 59: 42374241.
  • 37
    Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999; 59: 59385946.
  • 38
    Maliepaard M, van Gastelen MA, deJong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999; 59: 45594563.
  • 39
    Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993; 85: 271291.
  • 40
    Valkov NI, Sullivan DM. Drug resistance of DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 1997; 34 (Suppl 5): 4862.
  • 41
    Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol. 1997; 8: 837855.
  • 42
    Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994; 12: 530542.
  • 43
    Champoux JJ. Domains of human topoisomerase I and associated functions. Prog Nucleic Acid Res Mol Biol. 1998; 60: 111132.
  • 44
    Durban E, Goodenough M, Mills J, Busch H. Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells. EMBO J. 1985; 4: 29212962.
  • 45
    Kaiserman HB, Ingebritsen TS, Benbow RM. Regulation of Xenopus Laevis DNA topoisomerase I activity by phosphorylation in vitro. Biochemistry. 1988; 27: 32163222.
  • 46
    Pommier Y, Kerrigan D, Hartman KD, Glazer RL. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem. 1990; 265: 94189422.
  • 47
    Samuels DS, Shimizu N. DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-0-tetradecanoylphorbol-13-acetate and in vitro by protein kinase C. J Biol Chem. 1992; 267: 1115611162.
  • 48
    D'Arpa P, Liu LF. Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp Cell Res. 1995; 217: 125131.
  • 49
    Ferro AM, Olivera BM. (Poly-ADP-ribosylation) of DNA topoisomerase I from calf thymus. J Biol Chem. 1984; 259: 547554.
  • 50
    Kasid UN, Halligan B, Liu LF, Dritschilo A, Smulson M. (Poly)ADP-Ribose)-mediated post-translational modification of chromatin-associated human topoisomerase I. Inhibitory effects on catalytic activity. J Biol Chem. 1989; 264: 1868718692.
  • 51
    Adamietz P. Poly(ADP-ribose) synthase is the major endogenous nonhistone acceptor for Poly(ADP-ribose) in alkylated rat hepatoma cells. J Biochem. 1987; 169: 365372.
  • 52
    Boothman DA, Fukunaga N, Wang M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res. 1994; 54: 46184626.
  • 53
    Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr0DNA phosphodiesterase that repairs topoisomerase I complexes. Science. 1999; 286: 552555.
  • 54
    Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 1997: 272: 2415924164.
  • 55
    Mao Y, Sun M, Desai SD, Liu LF. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci USA. 2000; 97: 40464051.
  • 56
    Fujimori A, Gupta M, Hoki Y, Pommier Y. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol. 1996; 50: 14721478.
  • 57
    Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn LW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin-induced apoptosis. Cancer Res. 1993; 53: 18531861.
  • 58
    Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun. 1993; 192: 3036.
  • 59
    Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973; 33: 28342846.
  • 60
    Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res. 1972: 32: 26432650.
  • 61
    D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 1990; 50: 69196924.
  • 62
    Pizao PE, Smitskamp-Wilms E, Van Ark-Otte J, et al. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochem Pharmacol. 1994: 48: 11451154.
  • 63
    Erlichman C, Boerner SA, Hallgren CG, et al. The HER throsine kinase inhibitor CI1033 enhances cytotoxicity of SN-38 and topotecan by inhibiting BRCP-mediated drug efflux. Cancer Res. 2001; 61: 739748.
  • 64
    Cliby WA, Lilly KK, Lewis KA, Kaufmann SH. S and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem. 2002; 277: 15991606.
  • 65
    Prados M, Juhn J, Yng W, et al. A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium study [abstract 627]. Proc Am Soc Clin Oncol. 2000; 19: 12a.
  • 66
    Gilbert MR, Supko J, Grossman SA, et al. Dose requirements, pharmacology and activity of CPT-11 in patients with recurrent high-grade glioma. A NABTT CNS Consortium trial [abstract 622]. Proc Am Soc Clin Oncol. 2000; 19: 161a.